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Abstract
Insulin resistance (IR) and impaired insulin secretion contribute to type 2 diabetes and car-
diovascular disease. Both are associated with changes in the circulating metabolome, but
causal directions have been difficult to disentangle. We combined untargeted plasma meta-
bolomics by liquid chromatography/mass spectrometry in three non-diabetic cohorts with
Mendelian Randomization (MR) analysis to obtain new insights into early metabolic alter-
ations in IR and impaired insulin secretion. In up to 910 elderly men we found associations
of 52 metabolites with hyperinsulinemic-euglycemic clamp-measured IR and/or β-cell
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responsiveness (disposition index) during an oral glucose tolerance test. These implicated
bile acid, glycerophospholipid and caffeine metabolism for IR and fatty acid biosynthesis for
impaired insulin secretion. In MR analysis in two separate cohorts (n = 2,613) followed by
replication in three independent studies profiled on different metabolomics platforms (n =
7,824 / 8,961 / 8,330), we discovered and replicated causal effects of IR on lower levels of
palmitoleic acid and oleic acid. A trend for a causal effect of IR on higher levels of tyrosine
reached significance only in meta-analysis. In one of the largest studies combining “gold
standard” measures for insulin responsiveness with non-targeted metabolomics, we found
distinct metabolic profiles related to IR or impaired insulin secretion. We speculate that the
causal effects on monounsaturated fatty acid levels could explain parts of the raised cardio-
vascular disease risk in IR that is independent of diabetes development.
Author Summary
Impaired glucose homeostasis leads to diabetes and cardiovascular disease and has two
main components: failure to secrete enough insulin from pancreatic β-cells and reduced
insulin-stimulated cellular uptake of glucose and other nutrients in target tissues (insulin
resistance, IR).We usedmetabolomics analysis in non-diabetic persons to measure a non-
selective range of small molecules including amino acids, lipids, and sugars. Pathway analysis
highlighted distinctmetabolic pathways linked to IR (e.g. bile acid production) and impaired
insulin secretion (fatty acid biosynthesis), but causal directions remained unclear. Mendelian
Randomization (MR) analysis can test for causal effects in observational studies in the
absence of randomized controlled trials. Using MR analysis in up to four large independent
studies, we found evidence that IR causes a decrease in levels of the main endogenousmono-
unsaturated fatty acids palmitoleic acid and oleic acid, as well as suggestive evidence for
higher levels of the amino acid tyrosine.We provide a possible explanation for parts of the
diabetes-independent risk of cardiovascular disease in persons with IR.
Introduction
Insulin resistance (IR) is a major precursor of type 2 diabetes (T2D) [1], and constitutes an
independent risk factor for cardiovascular disease (CVD) [2] and for certain cancer types [3,
4]. In IR, the demands on pancreatic β-cells to produce insulin increase and blood glucose lev-
els rise if β-cell function is impaired. The metabolic effects of IR and declining β-cell function
are not fully characterized and causal relationships are difficult to disentangle due to the lack of
randomized controlled trials. Associations between the “gold standard” hyperinsulinemic-
euglycemic clamp method [5] for measuring whole-body IR and non-targeted metabolomics
profiling previously identifiedα-hydroxybutyrate as a biomarker for IR in 399 non-diabetic
persons [6]. Additional insights for causal directionsmay come from profiling circulating
metabolites combined with genotyping, as previously demonstrated in causal investigations of
adiposity and the metabolome using a Mendelian Randomization (MR) approach [7] and for
causal effects of uric acid on IR and T2D risk [8]. Mendelian randomization analysis can test
the causal relationship between an exposure and an outcome variable in the absence of ran-
domized controlled trials [9]. Exposure-associated single nucleotide polymorphisms (SNPs)
can be used as instrumental variables (IVs) because allelic variants are randomly allocated at
meiosis and therefore independent of bias from confounding and reverse causation. Genotype-
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datasets are made available to researchers who
meet the criteria for confidential data access as
stipulated by participant informed consent and
institutional review board/ethics committee
permission at the respective institution. Data from
TwinGene are available from the Swedish Twin
Registry steering committee (http://ki.se/en/
research/for-researchers; contact:
tvillingregistret@meb.ki.se). Data access in ULSAM
is granted through the Interdisciplinary
Collaboration Team on Uppsala Longitudinal
Studies (ICTUS; http://www2.pubcare.uu.se/
ULSAM/res/proposal.htm; contact: vilmantas.
giedraitis@pubcare.uu.se). Data from the PIVUS
study are available from the PIVUS steering
committee (http://www.medsci.uu.se/pivus/;
contact: lars.lind@medsci.uu.se). The Finnish
meta-GWAS used summary level data from six
cohorts and data access can be applied for here:
FINRISK, Helsinki Birth Cohort Study and Health
2000 (https://thl-biobank.elixir-finland.org/),
Northern Finland Birth Cohort 1966 (http://www.
oulu.fi/nfbc/node/18136), Cardiovascular Risk in
Young Finns Study (olli.raitakari@tutu.fi) and the
Finnish Twin Study contact: jaakko.
kaprio@helsinki.fi). Other summary level data used
in the study are available in the public domain at
http://mips.helmholtz-muenchen.de/proj/GWAS/
gwas/ (KORA/TwinsUK) and http://www.
chargeconsortium.com/ (CHARGE). Access to
individual participant data in KORA (https://epi.
helmholtz-muenchen.de/) and TwinsUK (contact:
victoria.vazquez@kcl.ac.uk) can be applied for.
Publicly available datasets in the EMBL-EBI
Expression Atlas (http://www.ebi.ac.uk/gxa/home)
were downloaded for the following accession
numbers: E-GEOD-5475, E-MEXP-893, E-GEOD-
2192, E-GEOD-38138, E-GEOD-2470, E-GEOD-
20636.
Funding: This study was supported by grants from
the Knut och Alice Wallenberg Foundation
(Wallenberg Academy Fellow), the Swedish
Diabetes Foundation (Diabetesfonden, grant no.
DIA 2013-024), the Family Ernfors Foundation
(Stiftelsen Familjen Ernfors fond), Lagermans
donation, Borgstro¨ms stiftelse, Go¨ran Gustafssons
stiftelse, the Swedish Heart-Lung Foundation
(Hja¨rt-Lungfonden, grants no. 20120197 and
20150429), the European Research Council (ERC-
2013-StG, grant no. 33595) and the Swedish
Research Council (Vetenskapsrådet, grants no.
2012-1397 and 2015-03477). TwinGene is a sub-
study of The Swedish Twin Registry, which is
financially supported by Karolinska Institutet.
TwinGene have also received funding from the
Swedish Research Council (grant no. M-2005-
1112), GenomEUtwin (EU/QLRT-2001-01254;
basedmethods like MR can inform drug targeting: For example, the association between
genetic variants in PCSK9, reduced low-density lipoprotein-cholesterol levels and lower coro-
nary heart disease risk [10] predicted the clinical success of pro-protein convertase subtisilin
kexin 9-inhibitors [11]. Conversely, MR studies confirmed the lack of a causal association
between plasma high-density lipoprotein-cholesterol and cardiovascular events [12].
The causal effects of impaired insulin secretion and IR on bloodmetabolites have not been
assessed before in a large-scale metabolomics framework and could pinpoint key mediators of
the risk of adverse health events. We aimed to identify metabolic pathways related to IR and
impaired early-phase insulin secretion during an oral glucose tolerance test (OGTT) in a large
European sample and applied MRmethods in additional cohorts to assess potential causal
effects of impaired insulin secretion and IR. Using non-targetedmetabolomics [13], we identi-
fied 52 circulatingmetabolites related to either IR or insulin secretion that implicated distinct
metabolic pathways and we found evidence for a causal effect of IR on reduced palmitoleic acid
(POA) and oleic acid (OA) levels, as well as on raised tyrosine levels.
Results
Metabolites associated with IR and impaired insulin secretion implicate
distinct metabolic pathways
The Uppsala Longitudinal Study of Adult Men (ULSAM) cohort of community-dwelling
71-year-old men provides the largest human sample combining plasma metabolomics with an
OGTTand the hyperinsulinemic-euglycemic clamp method.We previously developed a bioin-
formatics pipeline for untargeted liquid chromatography/mass spectrometry (LC/MS) data
[14] and were able to annotate among 10,162 spectral features 192 metabolites, on which this
study is based. In up to 910 non-diabetic individuals, we used linear regression adjusted for
age, sex, and sample quality indicators (S1 Text) to identify fasting metabolite levels associated
with physiologic measures of insulin secretion and IR. Table 1 provides sample characteristics
Table 1. Sample characteristics. Means ± standard deviation (SD) are shown for continuous, percentages for categorical variables (characteristics of rep-
lication cohorts are detailed in S1 Text).
ULSAM (n = 904) PIVUS (n = 944) TwinGene (n = 1,669)
Age 71.2 ± 0.5 70.2 ± 0.2 68.6 ± 8.3
% Male 100% 49.3% 41.1%
Current smoker 20.7% 10.6% 14.9%
Anti-hypertensive medication 31.1% 28.3% 25.2%
Lipid-lowering medication 8.9% 13.0% 15.1%
BMI (kg/m2) 25.9 ± 3.1 26.9 ± 4.2 26.0 ± 3.8
Total cholesterol (mmol/l) 5.8 ± 1.0 5.5 ± 1.0 5.8 ± 1.1
TG (mmol/l) 1.4 ± 0.7 1.3 ± 0.6 1.4 ± 0.8
LDL-C (mmol/l) 3.9 ± 0.9 3.4 ± 0.9 3.8 ± 1.0
HDL-C (mmol/l) 1.3 ± 0.4 1.5 ± 0.4 1.4 ± 0.4
Waist (cm) 94.8 ± 9.7 90.6 ± 11.4 92.9 ± 11.4
SBP (mmHg) 147.8 ± 18.9 149.2 ± 22.6 142.8 ± 20.5
DBP (mmHg) 84.3 ± 9.1 78.7 ± 9.9 82.3 ± 10.6
hs-CRP (mg/l) 3.2 ± 4.8 3.1 ± 4.5 3.6 ± 6.6
Clamp M/I (mg x kg-1 x kg BW-1 x min-1 per mU/l x 100) 5.4 ± 2.4 - -
Disposition index (M/I * IGI30) A 2.5 ± 3.3 - -
An = 899
BMI = body mass index, hs-CRP = high sensitivity C-reactive protein, DBP = diastolic blood pressure, HDL-C = high-density lipoprotein cholesterol,
LDL-C = low-density lipoprotein cholesterol, SBP = systolic blood pressure, TG = triglycerides
doi:10.1371/journal.pgen.1006379.t001
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and Fig 1 illustrates the study flow. Three outcomes were assessed: IR (clamp M/I), the insuli-
nogenic index (log-IGI30) as a measure of glucose-stimulated insulin secretion [15] and the
disposition index (log-DI) for β-cell responsiveness [16], all scaled to SD-units. At the 5% false
discovery rate (FDR), 47, 15, and zero metabolites were associated with clamp M/I, log-DI and
log-IGI30, respectively (Fig 2, S1 Table). Reduced levels of lysophosphatidylethanolamine
(LysoPE) 18:2 and hippuric acid were associated with IR and impaired insulin secretion.
Shared positive associations were found for deoxycholic acid glycine conjugate, corticosterone,
propranolol, piperine, and three unsaturated fatty acids (FAs; arachidonic, eicosatrienoic, and
oleic acid). Higher levels of glycerolipids and several acylcarnitines, and lower levels of glycero-
phospholipids were exclusively associated with IR. Further, increased levels of two bilirubin
species were exclusively associatedwith impaired insulin secretion. To identifymetabolite asso-
ciations independent of adiposity, we additionally adjusted each model for bodymass index
(BMI, S1 Table). This reduced the strength of associations to a lesser extent for impaired insu-
lin secretion than for IR and preserved the direction of associations for all metabolites still sig-
nificant at the 5% FDR (34 for IR and 8 for impaired insulin secretion). Six new associations
were detected for IR after BMI adjustment (increased levels of three acylcarnitines,α-tocoph-
erol, myristic acid and bilirubin, Fig 2). Pathway enrichment analysis carried out with Meta-
boAnalyst 3.0 [17] (http://www.metaboanalyst.ca/) indicated significant enrichment of IR-
associatedmetabolites in primary bile acid synthesis (p = 0.009, 4 metabolites),
Fig 1. Study flow and cohorts used in the different parts of the study.
doi:10.1371/journal.pgen.1006379.g001
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glycerophospholipid metabolism (p = 0.006, 4 metabolites) and caffeine metabolism (p = 0.016,
2 metabolites) (S1 Fig). Impaired insulin secretion-associatedmetabolites were enriched in the
FA biosynthesis pathway (p = 0.027, 3 metabolites).
In MR analysis, IR lowers POA, OA and hippurate levels
MR analysis in the discovery set. To examine causality in the association between insulin
response and metabolite levels, we took the 52 metabolites associated with either IR or
impaired insulin secretion in age- and sex-adjusted analysis forward to MR analysis in two sep-
arate Swedish cohorts—the Prospective Investigation of the Vascular in Uppsala Seniors
(PIVUS) and the TwinGene study. We used the previously validated additive allelic genetic
risk scores for IR (10 SNPs) and impaired insulin secretion (21 SNPs) as IVs [18] with proxies
in strong linkage disequilibrium (r2>0.8) in lieu of unavailable SNPs (S2 Table). Associations
between genetic scores and metabolites were assessed in linear models adjusted for age, sex, the
first three genetic principal components and cohort in PIVUS (n = 944) and TwinGene
(n = 1,669) (Fig 1). IV-exposure associations were obtained from Scott et al. [18] and causal
estimates were calculated as the ratio between the two regression coefficients (scaled to SD-
units). We detected evidence of causal effects of IR on lower levels of POA (βIV = –0.43, 95% CI
–0.85 to –0.01, p = 0.048) and hippuric acid (βIV = –0.91, 95% CI –1.66 to –0.16, p = 0.018)
(S3A Table). Causal effects that approached significance (p< 0.1) were detected for reduced
Fig 2. Metabolites associated with IR and impaired insulin secretion without (left panel) and after (right panel) adjustment for BMI. Based on
linear regression models in ULSAM (n = 904 for IR, n = 899 for impaired insulin secretion) adjusted for age and sample quality; significance threshold 5%
FDR.
doi:10.1371/journal.pgen.1006379.g002
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levels of OA (p = 0.074) and 3α,6β,7β-trihydroxy-5β-cholanoic acid (p = 0.079) as well as for
higher levels of monoacylglycerol (MAG) 18:1 (p = 0.079), MAG(18:2) (p = 0.064), MAG(14:0)
(p = 0.077), and γ-tocopherol (p = 0.084) (Fig 3 and S3 Table). Impaired insulin secretion
showed evidence of a causal effect on lower levels of the C24-bile acid 3α,6β,7β-trihydroxy-5β-
cholanoic acid (βIV = –0.36, 95% CI –0.68 to –0.04, p = 0.027) and there was a trend for a level-
raising effect on bilirubin (p = 0.071) (S3B Table).
The negative causal effect of IR on monounsaturated FA levels is
replicated in independent cohorts
We attempted replication for metabolites with suggestive evidence of causation (p< 0.1) in up
to 7,824 European individuals in the KORA F4/TwinsUK cohorts that underwent untargeted
Fig 3. Causal estimates (95% CI) for IR and impaired insulin secretion on metabolite levels. Estimates (p < 0.1) in the Swedish cohorts (PIVUS and
TwinGene, n = 2,613) and the replication studies (nKORA = 7,824, nCHARGE = 8,961, nFinnish = 8,330) are expressed as SD-unit change in metabolite levels
associated with a 1 SD increase in genetically determined IR (reduced clamp M/I) or impaired insulin secretion (reduced IGI30).
doi:10.1371/journal.pgen.1006379.g003
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metabolomics profiling on a different LC/MS platform [19]. The liberal p-value threshold was
chosen as a compromise between limited sample size and the risk of missing true positive asso-
ciations in the MR discovery set and we adopted the conventional threshold of p< 0.05 for sig-
nificance in all replication analyses. Seven of the nine causally implicated metabolites for IR
(excludingMAG(14:0) and 3α,6β,7β-trihydroxy-5b-cholanoic acid) and one of two (bilirubin)
for impaired insulin secretionwere available in KORA/TwinsUK. We replicated the causal
effect of IR on POA (βIV = –0.48, 95% CI –0.93 to –0.03 p = 0.038, all in SD-units) and the ten-
tative effect on OA (βIV = –0.38, 95% CI –0.81 to 0.04, p = 0.078) (Fig 3). We could not replicate
the causal effects on tyrosine (βIV = 0.20, 95% CI –0.19 to 0.59, p = 0.316) and hippuric acid
(βIV = –0.18, 95% CI –0.61 to 0.24, p = 0.398). A repeat analysis in a subset of 1,432 non-dia-
betic individuals in the KORA F4 cohort replicated the causal effect on POA (βIV = –1.14, 95%
CI –2.13 to –0.15, p = 0.024) and the tentative effect on OA (βIV = –0.82, 95% CI –1.75 to 0.10,
p = 0.082) (S1 Text).
In a second attempt to replicate the causal findings for POA and OA, we obtained the pub-
licly available GWAS results for FA fractions in plasma phospholipids from the Cohorts for
Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium (http://www.
chargeconsortium.com/main/results) [20]. The CHARGE study combines five independent
cohorts of 8,961 Europeans in age, sex, and recruitment site-adjusted meta-analysis and we
performedMR analysis based on the genetic IR score, as all 10 SNPs had been genotyped (S1
Text, FA fractions were converted to SD-units). The results replicated the causal effect of IR on
POA (βIV = –0.29, 95% CI –0.54 to –0.05, p = 0.018) and OA (βIV = –0.48, 95% CI –0.73 to –
0.24, p = 0.007).
We aimed to replicate the possible causal effect of IR on raised tyrosine using the summary
meta-GWAS results from five cohorts of 8,330 Finnish individuals who underwent nuclear
magnetic resonance metabolomics profiling [21]. In this sample, no significant effect on serum
tyrosine levels was found (β = 0.21, 95% CI –0.16 to 0.57, p = 0.267).
Achieving adequate power inMR analysis requires large sample sizes [22]. However, the dif-
ferences in analytical methods between studies for the samemetabolitemake the combination of
within-study effects in post-hocmeta-analysis methodologicallyunsound. To nonetheless explore
the effect of increased sample size on causal effects, we combined estimates for eachmetabolite in
inverse variance-weighted fixed-effectsmeta-analysis and illustrate these exploratory estimates in
Fig 3. In addition to the negative effects on POA and OA, the combined analysis indicated a
causal effect of IR on higher tyrosine levels (p< 0.05) that was observedas a non-significant
trend in each individual study. Given the risk of false positive findings due to multiple testing,
these post-hoc findings should be interpreted with caution and require confirmation studies.
MR sensitivity analysis does not indicate significant pleiotropy
To assess for violations of MR assumptions due to genetic confounding, horizontal pleiotropy
and IV heterogeneity, we examined a) the association of individual SNPs with the risk factors
(S2B Fig)); b) the association of IVs with potential confounders (S3C Fig)); c) scatter plots of
IV-outcome v. IV-risk factor associations and funnel plots of IV strength v. IV estimate (S4D
Fig)); d) implemented sensitivity analysis for individual SNPs in inverse variance-weighted,
log-likelihoodand MR Egger regression, including heterogeneity tests (S4 Table, S1 Text [23–
25]); and e) discuss in S1 Text the likelihoodof bias from canalization and other effects.
We tested for associations of genetic scores with potential mediator variables in age- and
sex-adjusted linear regression in ULSAM, PIVUS and TwinGene (S3 Fig) and confirmed the
association betweenworse genetic IR and lower HDL-C as well as smaller waist-hip ratio as
reported by Scott et al. [18] (who included ULSAM), and found an association with higher
Metabolomics of Insulin Resistance and Impaired Insulin Secretion
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albumin levels. As in [18], the impaired insulin secretion score was positively associated with
plasma glucose and unrelated to other traits apart from lower albumin levels and a trend for
increased C-reactive protein. For all metabolites with indication for a causal effect (p< 0.1) in
the MR discovery sample, we examined individual SNP effects on metabolite levels. The IV-
exposure associations were derived from the GWAS results for homeostasis model assessment-
IR (HOMA-IR, n = 46,186) and corrected insulin response (CIR, n = 5,318) in non-diabetic
persons from the publicly available results of the Meta-Analyses of Glucose and Insulin-related
traits Consortium (MAGIC; http://www.magicinvestigators.org/downloads/, converted to SD-
units). The association between SNPs and risk factors in MAGIC were consistent and did not
indicate heterogeneity apart from one variant (rs11605924) that was associated with CIR in the
unexpecteddirection (S2 Fig). As reported in S4 Table, Cochran’s Q tests failed to detect signif-
icant heterogeneity between individual SNPs’ causal estimates. The significant effects of IR on
OA and POA levels detected in the main analysis were replicated in all sensitivity tests except
in the case of MR Egger regression for POA (slope estimate –0.96, 95% CI –2.15 to 0.22,
p = 0.095). Although the intercept estimate in MR Egger regression for OA differed signifi-
cantly from zero, it was small in magnitude (intercept estimate 0.02, 95% CI 0.00 to 0.04,
p = 0.018) and the causal effect was reproduced (slope estimate –0.49, 95% CI –0.82 to –0.16,
p = 0.010). One important assumption of MR Egger regression–that any pleiotropic effects of
IVs on the outcome be independent of IV strength [23]–cannot be assessed with currently
available methods. Because the IV score had been carefully constructed by Scott et al. [18] to
limit the likelihoodof pleiotropic interference (particularly from BMI) and based on the total-
ity of all MR sensitivity analyses that reproduced the main results in direction and magnitude
and failed to indicate significant heterogeneity, we are confident to have excluded pleiotropic
effects that could invalidate our main findings as far as possible. However, as discussed in S1
Text, some sources of bias (e.g., canalization) cannot be excluded and the possibility of remain-
ing pleiotropic effects pose limitations that mandate careful interpretation of any MR study.
Publicly available gene expression data support the causal effects on
OA and POA
To further assess our findings of a negative causal effect of IR on monounsaturated FA levels,
we looked up gene expression data for SCD1 and its rodent equivalent scd1 in the EMBL-EBI
Expression Atlas v3.0 (http://www.ebi.ac.uk/gxa/home). This gene encodes stearoyl-CoA desa-
turase 1 (SCD-1), the rate-limiting enzyme in the biosynthesis of OA and POA [26]. Among
252 uploaded experiments that reported significantly different expression (5% FDR) between
experimental and control conditions, we extracted all experiments related to IR. There were
eight studies in mice and rats–none in human beings (S1 Text). In all instances, the direction
of differential scd1 expression was consistent with our findings—the IR-increasing condition
down-regulated scd1 expression.
Discussion
In the observational part of this multi-cohort study of bloodmetabolomics profiles, we identi-
fied bile acid, glycerophospholipid and caffeine metabolism as associated with IR, and FA bio-
synthesis as related to impaired insulin secretion.We discovered and replicated causal effects
of IR on lower levels of the monounsaturated FAs POA and OA, as well as suggestive evidence
for higher levels of the aromatic amino acid tyrosine. Sensitivity analyses did not indicate pleio-
tropic effects of the genetic instruments. Causal effects were largely unaffected by the exclusion
of prevalent diabetes cases in the KORA/TwinsUK replication set. A small collection of pub-
licly available experimental results in rodents supported our causal findings: All IR-increasing
Metabolomics of Insulin Resistance and Impaired Insulin Secretion
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conditions were associated with a down-regulation of SCD-1, implying reduced endogenous
production of OA and POA.
The liver and adipose tissue are the main sites of de novo lipogenesis and SCD-1 is the rate-
limiting enzyme for monounsaturated FA biosynthesis [27]. It introduces double bonds into
palmitic and stearic acid to produce POA (16:1n-7) and OA (18:1n-9), respectively–themajor
precursors for cholesteryl esters and triglycerides (TGs) that are packaged into very low-density
lipoprotein (VLDL) particles and secreted by the liver [28]. In scd1 knockout mice and hyper-
triglyceridemicpersons, plasma FA composition reflects hepatic SCD-1 activity [29, 30].
Hence, whilst dietary FAs contribute to overall plasma FA levels, the relative lipid composition,
as assessed in the present study, is likely to reflect SCD-1 activity. Correspondingly, in ULSAM
and PIVUS, we found good agreement between FA quantification by untargeted plasma meta-
bolomics and targeted serum cholesteryl ester analysis (S1 Text).
Experimental evidence for the inhibition of SCD-1 by IR stems from liver-specific insulin
receptor knockout (LIRKO) mice that had ~80% reduced hepatic scd1 expression and ~90%
reducedmicrosomal scd1 transcript levels compared to control mice [31, 32]. In muscle-spe-
cific insulin receptor knockout (MIRKO) mice, scd1 expression was downregulated by ~23%
compared to controls [33].
Little is known about the causal effects of a genetic predisposition for IR on SCD-1 [34].
Reduced SCD-1 activity in knockout mice has beneficialmetabolic consequences, including
reduced obesity [35] and improved IR [36] (reviewed in [28] and [34]). Yet, reduced SCD-1
activity has also been associated with adverse vascular outcomes: Inhibition of SCD-1 in hyper-
lipidemic mice markedly increased aortic atherosclerosis despite protective effects on obesity
and IR [37]. Reduced SCD-1 activity caused enrichment of saturated FA in VLDL and LDL,
which promoted atherogenesis throughmacrophage-induced vascular inflammation. Suscepti-
bility to exacerbated inflammation was also demonstrated in scd1 knockout mice with induced
colitis [38] or on a very low-fat diet that increased endoplasmic reticulum stress response [39].
Based on these competing effects on vascular and metabolic health, we speculate that IR
reduces SCD-1 activity, which counteracts the metabolic consequences of IR by improving
insulin signaling but concomitantly increases the risk for CVD through saturated FA-induced
proinflammatory changes. Supported by our results and the above evidence, this hypothesis
further derives from two facts: IR increases CVD risk independent of other risk factors [2, 40]
and IR predicts CVD risk independent of T2D [41]. A summary of the presumed relationships
is displayed in Fig 4. In our study, we could not evaluate the longitudinal effect on CVD, hence
our hypothesis needs to be evaluated in cohorts with the available outcome data. In observa-
tional analysis, IR was positively associated with OA (FDR-adjusted p = 0.035, after adjustment
for BMI pBMI> 0.05) and POA levels (p = 0.091, pBMI> 0.1) in contrast to the negative genetic
associations in MR studies. This discrepancy is likely due to confounding factors such as die-
tary FA intake and highlights that MR studies have the power to disentangle causal mecha-
nisms that may be obscured in cross-sectional studies. The hypothesized but untested
relationship with cardiovascular disease requires investigation in future studies.
The effect of IR on elevated tyrosine levels was observed as a non-significant tendency in all
cohorts but reached nominal significance only after combination of estimates in meta-analysis.
Although there is a considerable risk that this result is a false positive due to multiple testing,
we still consider it an interesting finding worth investigating in larger MR studies, as it has not
been reported before. Associations betweenworse IR/T2D risk and circulating tyrosine levels
have been established in observational and longitudinal studies [42, 43]. Possible molecular
mechanisms could involve reduced tyrosine catabolism, either through IR-induced oxidative
stress leading to elevations in methionine, cysteine and the antioxidant glutathione that result
in tyrosine hydroxylase inhibition [44]; or through inactivation of tyrosine aminotransferase
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[45]. Hence, we speculate that the previously identified association between tyrosine and
increased T2D risk could be caused by concomitant IR but caution that the observed trends in
our study need to be verified in larger samples.
Limitations of our study include moderate power in MR studies and inherent limitations of
the non-targetedmetabolomics discovery platform to capture certainmetabolites (e.g., polar
amino acids) and separate sugars and other non-polar molecules.We used an untargeted meta-
bolomics approach that detected several thousand metabolic features, yet the limited availabil-
ity of standard compound spectra in in-house and public libraries precluded the quantification
of the entire spectrumof the plasma metabolome and may have biased the pathway enrich-
ment analysis. Observational associations were established in an exclusively male, elderly Euro-
pean cohort (ULSAM) with unknown generalizability to other age and ethnic groups. The
different metabolomics platforms between studies and the expression of FA levels in % of
plasma phospholipids rather than absolute levels in CHARGE somewhat limit methodological
consistency. However, this diversity also supports the robustness of findings that were repli-
cated on different platforms. Causal relationships were consistent across studies but require
validation in physiologic models of IR, particularly as some sources of bias (e.g., canalization,
unmeasured horizontal pleiotropy) cannot be excluded.Whilst the unique contribution of our
study is to assess causal effects on the plasma metabolome, we could not examine the reverse
causality as no genetic instruments were available for the majority of metabolites. As illustrated
Fig 4. Schematic summary of the presumed effects of IR on SCD-1 and associated consequences. Abbreviations: IR–insulin resistance, LDL–low
density lipoprotein, OA–oleic acid, POA–palmitoleic acid, SCD-1 –stearoyl CoA-desaturase 1, SFA–saturated fatty acid, TG—triglycerides, VLDL–very low
density lipoprotein
doi:10.1371/journal.pgen.1006379.g004
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above, relative levels of circulating POA and OA likely reflect endogenous biosynthesis, how-
ever, the exact contributions of SCD-1, exogenous sources, catabolism and excretion could not
be addressed by our study and require experimental investigation. We used proxy outcomes
(HOMA-IR and CIR) with available large GWAS results in sensitivity analyses rather than the
exact same measures as in the main analysis.
Strengths include the extensive testing for violations of MR assumptions, the replication of
main findings in large independent cohorts that used different methods of quantification, and
the use gold standard measures for IR.We detected no evidence of pleiotropy of genetic instru-
ments whose associations with cardiometabolic traits were in the expected directions and
causal estimates agreed between different analysis methods.
In summary, our study in multiple independent cohorts of community residents indicates a
causal effect of IR on circulatingOA, POA, and tyrosine levels and provides new insights into the
metabolomic signature of IR and impaired insulin secretion. It is to our knowledge the first large-
scale attempt to explore the causal effects of genetic IR on a non-selected set of plasma metabo-
lites. The potential implications of the presumed IR-induced inhibition of monounsaturated FA
biosynthesis on health outcomes require validation in experimentalmodels but may form part of
the explanation for the elevated CVD risk in IR that is independent of T2D development.
Materials and Methods
Cohort description
Detailed descriptions are available in S1 Text. In brief, ULSAM (http://www2.pubcare.uu.se/
ULSAM/) was started in 1970 and enrolled 81.7% (n = 2,322) of all male residents of Uppsala
county, Sweden, born between 1920 and 1924. On-going assessments every five to ten years
include questionnaire, biochemical, and anthropometric examinations. The current study is
based on the assessment at age 70 years, which included an OGTTand hyperinsulinemic-
euglycemic clamp measurement.
The PIVUS study (http://www.medsci.uu.se/pivus/) enrolled 50% (n = 1,016) of a random
sample of Uppsala community residents aged 70 years in 2001 and features assessments includ-
ing health questionnaires, blood sampling and clinical measurements every five years. The cur-
rent study is based on the assessment at age 70 years.
TwinGene (http://ki.se/en/meb/twingene-and-genomeeutwin) is a longitudinal study of
12,591 twins born before 1958 and registered in the Swedish Twin Registrywith questionnaire
assessments and blood sampling done between 1998 and 2002, and again between 2004 and
2008. The current study used a subcohort from a nested case-cohort design established for an
earlier project [13] that was randomly selectedwithin four age and sex strata to match a case
group that included incident cases of T2D, coronary heart disease, ischemic stroke, and demen-
tia (up to 31 Dec 2010) (S1 Text). In all three Swedish cohorts, prevalent cases of diabetes were
excluded (criteria in S1 Text).
The CooperativeHealth Research in the Region of Augsburg (Kooperative Gesundheits-
forschung in der Region Augsburg, KORA [46]) study is a series of epidemiological surveys of
the general population in SouthernGermany that includes longitudinal health assessment and
blood sample collection. The current study is based on the KORA F4 (2006–2008) survey of
32-to-77-year-old men and women (n = 1,768, 48.5%male, mean age 60.8 ± 8.8 years, mean
BMI 28.2 ± 4.8 kg/m2).
TwinsUK is a predominantly female cohort of adult twins recruited from the general UK
population. The current study is based on 17-to-85-year-old twins (n = 6,056, 7.1%male, mean
age 53.4 ± 14.0 years, mean BMI 26.1 ± 4.9 kg/m2) who underwent bloodmetabolite profiling
and health center assessment.
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The CHARGE consortiumGWAS for plasma FA fractions [20] combined 8,961 mostly
middle-aged to older persons of European ancestry (45.0%male, mean age 59.7 ± 7.6 years,
mean BMI 27.0 ± 4.8 kg/m2) from five cohorts—the Atherosclerosis Risk in Communities
(ARIC) study, the CardiovascularHealth Study (CHS), the Coronary Artery Risk Development
in Young Adults (CARDIA) study, the Invecchiare in Chianti (InCHIANTI) study, and the
Multi-Ethnic Study of Atherosclerosis (MESA). Details on cohorts and recruitment are
reported elsewhere [20] and documented online (http://chargeconsortium.com/).
The Finnish consortium [21] combined five cohorts of 8,330 individuals with serumnuclear
magnetic resonance metabolomics results from the FINRISK 2007 Dietary, Lifestyle and Genetic
determinants of Obesity and Metabolic syndrome (FINRISK-07/DILGOM) study, the Helsinki
Birth Cohort Study (HBCS), the Health2000 GenMets study, the Northern Finland Birth Cohort
1966 (NFBC1966) study and the Cardiovascular Risk in Young Finns Study (YF). Across all
cohorts with 46.9%males, mean age was 37.8 ± 3.2 years and mean was BMI 25.4 ± 4.3 kg/m2.
Ethics statements
All participants provided written informed consent prior to inclusion in the study and the
research was approved by the Ethics Committees of Uppsala University (ULSAM, PIVUS) and
Karolinska Institutet (TwinGene), or the respective Institutional ReviewBoards for the other
cohorts. The study was conducted according to the principles of the Declaration of Helsinki.
Metabolomics profiling
Untargeted metabolomics profiling of venous blood samples in the three Swedish cohorts was
carried out by ultra-performance liquid chromatography (UPLC) on a Waters Acquity UPLC
system coupled to a Waters Xevo G2-Time-Of-Flight-Mass Spectrometry (TOFMS) platform
at Colorado State University (Fort Collins, CO, USA). Data acquisition in the positive electro-
spray ion mode with a mass-to-charge ratio (m/z) range of 50–1,200 at 5 Hz was alternately
performed at collision energies of 6V and 15–30V. Details on sample handling and data pro-
cessing by XCMS in R [47] are available in S1 Text and in [14]. Parameter selection for feature
detection, alignment, grouping, and imputation was optimized in simulations of random sets
of 20–40 samples. In total, 10,162 (ULSAM), 9,755 (TwinGene) and 7,522 (PIVUS) features
were detected. Adjustment for factors of unwanted variability (plate effect, analysis date, reten-
tion time drift and sample collection) by analysis of variance-type standardization was followed
by log-transformation and removal of spectra with abnormal intensities and/or low inter-
duplicate correlations and/or retention times<35 sec. For each feature, retention time, m/z,
and fragmentation pattern were compared to in-house and public database reference libraries
and matched according to Metabolomics Standard Initiative guidelines [48]. The current study
is based on all 192 metabolites identified in ULSAM. Common features betweenULSAM,
PIVUS, and TwinGene were identified by matching m/z and retention time, followed by man-
ual inspection of fragmentation spectra. Full metabolomics data are available in the Metabo-
Lights archive (study identifiersMTBLS90 for PIVUS, MTBLS124 for ULSAM,MTBLS93 for
TwinGene; http://www.ebi.ac.uk/metabolights/).
Metabolomics analyses in KORA and TwinsUK were carried out by the commercial company
Metabolon, Inc. (Durham, NC, USA), which combined positive and negative ion-modeUPLC/
tandem-MSwith gas chromatography/MS. Following protein precipitation in methanol, samples
for analyzed in duplicates and spectral annotation was performed against a standard compound
library (for details, see S1 Text and [19, 46]). Following the removal of outlying (>3 SD) features
and those with<300 non-missing values, 276 and 258 metabolites in KORA and TwinsUK,
respectively, were quantified and identified based on matching to in-house library standards.
Metabolomics of Insulin Resistance and Impaired Insulin Secretion
PLOS Genetics | DOI:10.1371/journal.pgen.1006379 October 21, 2016 12 / 19
In CHARGE, a targeted gas chromatography approach was used to quantify plasma phos-
pholipid composition (except in the InCHIANTI cohort, where total plasma FA were mea-
sured). As detailed in [20], fasting plasma phospholipid isolation by thin-layer
chromatography was followed by quantification of FA by targeted gas chromatography.
The Finnish study processed serum samples from all five sub-cohorts in one central labora-
tory by three complementary 1H-nuclear magnetic resonance analysis windows optimized for
lipoproteins, low molecular weight metabolites and lipid species, respectively [21, 49]. For
quantitative analysis, raw spectral data were pre-processed with baseline zeroing, peak align-
ment and correction for albumin background and validated against high-performanceLC data.
Statistical analysis
Outcomemeasures in ULSAM. The outcomes were insulin sensitivity (clamp M/I in mg
x kg-1 x kg body weight-1 x min-1 per mU / l x 100; representing the amount of glucosemetabo-
lized per unit of plasma insulin during the clamp assessment), the insulinogenic index (IGI30)
as a measure of glucose-stimulated insulin secretion [15] (calculated as the increment in
plasma insulin divided by the change in plasma glucose levels between 0–30 min during the
OGTT, log-transformed to normality), and the disposition index (DI) for β-cell responsiveness
[16] (the product of clamp M/I x IGI30, log-transformed to normality). All outcomes were
scaled to SD-units prior to analysis.
Association testing in ULSAM. Details on the OGTTand hyperinsulinemic-euglycemic
clamp testing (modified according to [5]) are available in S1 Text. Separate multivariable age-
adjusted linear regression analyses with or without additional adjustment for BMI were carried
out for bloodmetabolite levels (standardized to mean = 0, SD = 1) as predictors for clamp M/I,
IGI30 [15] and DI [16]. Non-normal distribution according to histograms required natural
log-transformation for IGI30 and DI. Model assumptions were ascertained in residual-by-
fitted value plots and outliers screened for in histograms and plots of Cook’s distance. Metabo-
lites with significant associations after adjustment for multiple testing at the 5% FDR were
taken forward to MR analysis. All analyses were performed in R v3.1.1. To ease understanding,
in the manuscript all associations are expressed in the direction of worsening IR and impaired
insulin secretion (except in S1 Table where associations with the actual measure–clampM/I,
DI, and IGI30 –are presented).
MR analysis
We used IV analysis to estimate the causal effect of IR/impaired insulin secretion on metabolite
levels in PIVUS and TwinGene. TheWald ratio estimator [50] was obtained as the ratio
between the regression coefficients for the effect of the genetic IV on metabolite levels divided
by the effect of the genetic IV on IR/insulin secretion (Eq 1). Standard errors were estimated by
the deltamethod, which we previously validated (Eq 2) [51].
bIV ¼
bIV   Metabolite
bIV   Exposure
SEIV ¼ ABSðbIVÞ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SEIV   Metabolite
bIV  Metabolite
 2
þ
SEIV   Exposure
bIV  Exposure
 !2
v
u
u
t
Eq 1 and 2. Causal estimator (βIV) and standard error (SEIV) calculations based on regres-
sion coefficients and corresponding SEs for the IV in linear models with exposure or metab-
olite levels as outcome.
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As IV, we used the IR and impaired insulin secretion genetic risk scores validated by Scott
et al. [18] (S2 Table). Because the study included ULSAM (alongside the MRC-Ely, RISC, Fen-
land, and EPIC-Interact cohorts) to estimate the association between instrument and risk fac-
tor, we excluded the ULSAM cohort fromMR analysis. We used proxy SNPs (linkage
disequilibium r2>0.8) for variants not directly genotyped.When no proxies were available,
SNP scores were imputed as 2risk allele frequency based on the 1000 Genomes Project phase
1 [52] (for the insulin secretion score this applied to rs1800574 in all three cohorts, as well as
rs7957197 and rs10811661 in TwinGene) (S2 Table). Quality control includedmean-imputa-
tion of SNP values for individuals with one missing value and exclusion of individuals with>1
missing values. All SNPs had call rates>95%. Additive non-weighted genetic risk scores were
calculated in PLINK1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/).The association
between genetic IVs and metabolites was estimated in linear models adjusted for age, sex, the
first three genetic principal components and cohort with metabolite levels (SD-unit) as out-
come. Age- and sex-adjusted associations between genetic IVs and exposure (SD-unit) were
obtained from Scott et al. [18]. For sensitivity analysis, SNP associations with IR and insulin
secretionwere obtained from summaryGWAS results in MAGIC (see above). MR Egger
regression and other sensitivity analyses were carried out in R according to the scripts provided
in the data supplement by [23] and in appendix A.3 by [24], respectively.
Replication in KORA/TwinsUK, CHARGE, and the Finnish cohorts
We obtained the publicly available GWAS data for serum/plasmametabolite levels in 7,824
European adults in the KORA F4 and TwinsUK cohorts [19], as well as for OA and POA frac-
tions of total plasma phospholipids in 8,961 Europeans in CHARGE http://chargeconsortium.
com/).We also obtained the summarymeta-GWAS statistics for serum tyrosine levels from a
Finnish consortium study [21]. Details on genotyping and statistical analyses are available in
S1 Text and elsewhere [19, 46]. We extracted β coefficients and standard errors for SNPs in the
non-weighted IR/insulin secretion genetic scores and computed summary effect sizes with the
grs.summary() function in the gtx package in R [53]. Regression coefficients expressed SD-unit
change in metabolite levels. Causal effects were estimated by MR analysis as described above
for all metabolites available in KORA/TwinsUK that passed p< 0.1 at the discovery stage, for
OA and POA in CHARGE, and for tyrosine in the Finnish consortium. Causal estimate from
all cohorts were combined in inverse variance-weighted, fixed effectsmeta-analysis viametafor
in R.
R scripts for the full metabolomics pipeline in PIVUS, TwinGene and ULSAM are available
online (https://github.com/andgan/metabolomics_pipeline), R scripts used for observational
and MR analysis are available as well (https://github.com/chrnowak/metabolomics).
Supporting Information
S1 Text. Supplemental methods and results.
(DOCX)
S2 Text. Product ion spectra from liquid chromatography/tandemmass spectrometryanal-
ysis of selectedmetabolites and their corresponding standards that were used for annota-
tion in ULSAM, PIVUS, and TwinGene.
(DOCX)
S1 Fig. Metabolic pathway enrichment for 47 IR-associatedmetabolites and 15 impaired
insulin secretion-associatedmetabolites in observational analysis.
(TIF)
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S2 Fig. Associations between genetic risk scores for IR (S2A Fig) and impaired insulin
secretion (S2B Fig) with HOMA-IR and CIR, respectively, in MAGIC.
(TIF)
S3 Fig. Associations between genetic risk scores for IR (upper panel) and insulin secretion
(lower panel) with cardiometabolic traits in ULSAM, PIVUS and TwinGene. Based on lin-
ear regression adjusted for age, sex, and cohort. Beta coefficients and 95% CIs indicate the SD-
unit change in trait level per added risk allele. ALP = alkaline phosphatase, ALT = alanine
amino transferase, ApoA1/B = apolipoprotein A1/B, BMI = bodymass index, CK = creatinine
kinase, CRP = C-reactive protein, DBP = diastolic blood pressure, Hb = hemoglobin,HDL-
chol = high-density lipoprotein cholesterol, IGI30 = insulinogenic index, IL-6 = interleukin-6,
LDL-chol = low-density lipoprotein cholesterol, SBP = systolic blood pressure, TG =
triglycerides,WHR = waist-hip ratio
(TIF)
S4 Fig. MR sensitivity plots for top metabolites in all cohorts: scatter plots of genetic associ-
ations with the outcome against genetic associationswith the risk factor, and funnel plots
of IV strength against IV estimate.
(PDF)
S1 Table. Associations between clampM/I, IGI30, and DI with fasting metabolite levels in
ULSAM.
(XLSX)
S2 Table. Genetic score SNPs and availability in the discovery cohorts.
(XLSX)
S3 Table. MR analysis results for causal effects of IR and impaired insulin secretion on
metabolite levels in the discovery cohorts.
(XLSX)
S4 Table. Results of MR sensitivity analysis for top metabolites.
(XLSX)
S5 Table. Metabolic features, annotation levels and main adduct form in liquid chromatog-
raphy/tandemmass spectrometryanalysis in ULSAM, PIVUS, and TwinGene.
(XLSX)
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